… Compared With Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. -
WP McGuire, WJ Hoskins, MF Brady, PR Kucera, EE … - Obstetrical & Gynecological Survey, 1996 - obgynsurvey.com
... cancer. Anti-Cancer Drugs. 14(8):633-638, September 2003. Recchia ... carcinoma.
Anti-Cancer Drugs. 14(5):347-352, June 2003. Gallardo ...

… of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part II -
JD Hayes, DJ Pulford - Critical Reviews in Biochemistry and Molecular Biology, 1995 - informaworld.com
Page 1. UI Y I uu Mutation T 9 + AG G A 4+ + + AG 4+ A 4G Nucleotide 704 703 702
701 700 699 698 697 696 695 694 693 692 691 690 689 688 687 ratGSTA2-ARE G C T ...

MRP3, an organic anion transporter able to transport anti-cancer drugs -
M Kool, M van der Linden, M de Haas, GL Scheffer, … - Proc Natl Acad Sci US A, 1999 - pubmedcentral.nih.gov
... We discuss the possible function of MRP3 in (hepatic) physiology and its
potential contribution to drug resistance of cancer cells. ...

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. -
T Boehm, J Folkman, T Browder, MS O'Reilly - Nature, 1997 - ncbi.nlm.nih.gov
... Antiangiogenic therapy of experimental cancer does not induce acquired drug
resistance. Boehm T, Folkman J, Browder T, O'Reilly MS. ...

Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 ( … -
F Ciardiello, R Caputo, R Bianco, V Damiano, G … - Clinical Cancer Research, 2000 - AACR
... A dose-dependent supra-additive increase in growth inhibition was observed when
cancer cells were treated with each cytotoxic drug and ZD-1839. ...

The National Cancer Institute: cancer drug discovery and development program. -
MR Grever, SA Schepartz, BA Chabner - Semin Oncol, 1992 - ncbi.nlm.nih.gov
Semin Oncol. 1992 Dec;19(6):622-38. The National Cancer Institute: cancer drug
discovery and development program. Grever MR, Schepartz SA, Chabner BA. ...

Histone deacetylase inhibitors as new cancer drugs. -
PA Marks, VM Richon, R Breslow, RA Rifkind - Current Opinion in Oncology, 2001 - co-oncology.com
... acute promyelocytic leukemia [6]. Phase I trials with phenylbutyrate have been
performed at the National Cancer Institute [6?]. The drug generally was well ...

… Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer 1 -
T Browder, CE Butterfield, BM Kraling, B Shi, B … - Cancer Research, 2000 - AACR
... When Lewis lung carcinoma and EMT-6 breast cancer were made drug resistant before
therapy, the antiangiogenic schedule suppressed tumor growth 3-fold more ...

[PDF] Angiogenesis in cancer and other diseases -
P Carmeliet, RK Jain - Nature, 2000 - cmbi.bjmu.edu.cn
... Similarly, without an efficient blood supply we may not be able to deliver
anti-cancer drugs to all regions of a tumour in effective quantities. ...
-

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening -
P Skehan, R Storeng, D Scudiero, A Monks, J … - jnci, 1990 - jnci.oxfordjournals.org
... D. Panda, and HC Joshi Development of a Novel Nitro-Derivative of Noscapine for
the Potential Treatment of Drug-Resistant Ovarian Cancer and T-Cell Lymphoma Mol ...